Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications.

Abstract

OBJECTIVES:

Inflammatory breast carcinoma (IBC) is rare but is the most lethal type of breast cancer. Programmed death ligand 1 (PD-L1) expression in IBCs has been understudied.

METHODS:

In this study, tissue microarrays of 68 IBCs were immunostained with a PD-L1 antibody using an antibody clone (28-8) and detection system approved by the US Food and Drug Administration for selecting patients with non-small cell lung cancer and melanoma for anti-PD-L1 therapy.

RESULTS:

Positive PD-L1 expression was found in 25 (36.8%) of 68 samples but was not significantly associated with the clinicopathologic variables examined. Univariate analysis of overall survival (OS) revealed that worse OS was significantly associated with positive PD-L1, negative estrogen receptor, and triple-negative status. The 5-year OS rate was 36.4% for patients with PD-L1-positive IBC and 47.3% for those with PD-L1-negative IBC. In multivariate analyses, PD-L1 status remained a statistically independent predictor of OS.

CONCLUSIONS:

These findings indicate that PD-L1 inhibitors could potentially improve the clinical outcome of patients with PD-L1-positive IBC.

• Authors: Jing He, Lei Huo, Junsheng Ma, Jun Zhao, Roland L Bassett, Xiaoping Sun, Naoto T Ueno, Bora Lim, Yun Gong
• Journal: American journal of clinical pathology (Am J Clin Pathol) Vol. 149 Issue 3 Pg. 253-261 (Feb 17 2018) ISSN: 1943-7722 [Electronic] England
• PMID: 29425258 (Publication Type: Journal Article)
• Copyright: © American Society for Clinical Pathology, 2018. All rights reserved. For permissions, please e-mail: [email protected]

Chemical References

• B7-H1 Antigen
• Biomarkers, Tumor
• CD274 protein, human

Topics

• Adult
• Aged
• Aged, 80 and over
• B7-H1 Antigen (metabolism)
• Biomarkers, Tumor (metabolism)
• Carcinoma, Ductal, Breast (diagnosis, metabolism, mortality, therapy)
• Carcinoma, Lobular (diagnosis, metabolism, mortality, therapy)
• Female
• Follow-Up Studies
• Humans
• Immunohistochemistry
• Inflammatory Breast Neoplasms (diagnosis, metabolism, mortality, therapy)
• Middle Aged
• Prognosis
• Retrospective Studies
• Survival Analysis
• Tissue Array Analysis